Adenosine receptors and their modulators.
暂无分享,去创建一个
C. Müller | T. Scior | C E Müller | T Scior
[1] N. Peet,et al. Conformationally restrained, chiral (phenylisopropyl)amino-substituted pyrazolo[3,4-d]pyrimidines and purines with selectivity for adenosine A1 and A2 receptors. , 1992, Journal of medicinal chemistry.
[2] J. Dumont,et al. Cloning and functional characterization of a human A1 adenosine receptor. , 1992, Biochemical and biophysical research communications.
[3] J. Fergus,et al. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.
[4] B. K. Trivedi,et al. N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor. , 1988, Journal of Medicinal Chemistry.
[5] J. Linden. Adenosine deaminase for removing adenosine: how much is enough? , 1989, Trends in pharmacological sciences.
[6] H. W. Hamilton,et al. Synthesis and structure-activity relationships of pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists. , 1987, Journal of medicinal chemistry.
[7] A. IJzerman,et al. 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. , 1991, Journal of medicinal chemistry.
[8] K. Jacobson,et al. Autoradiographic localization of mouse brain adenosine receptors with an antagonist ([3H]xanthine amine congener) ligand probe , 1988, Neuroscience Letters.
[9] R. F. Bruns. Structure Activity Relationships for Adenosine Antagonists , 1990 .
[10] A. Bridges,et al. N6-bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor. , 1989, Journal of medicinal chemistry.
[11] J. Daly,et al. 7-Deaza-9-phenyladenines. A new class of adenosine receptor antagonists. , 1988, Biochemical pharmacology.
[12] B. Cronstein,et al. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[13] Sergi Ferré,et al. Antagonistic A2a/D2 receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system , 1993 .
[14] C. Müller,et al. Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. , 1993, Journal of medicinal chemistry.
[15] L. Miller,et al. High selectivity of novel isoguanosine analogues for the adenosine A1 receptor , 1991 .
[16] K. Jacobson,et al. Adenosine receptor prodrugs: towards kidney-selective dialkylxanthines. , 1989, The Journal of pharmacology and experimental therapeutics.
[17] A S Clanachan. Antagonism of presynaptic adenosine receptors by theophylline 9-beta-D-riboside and 8-phenyltheophylline. , 1981, Canadian journal of physiology and pharmacology.
[18] M. Williams,et al. Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. , 1992, Journal of medicinal chemistry.
[19] R. Olsson,et al. Coronary vasoactivity of novel N6-substituted adenosines , 1991 .
[20] D. Mckenna,et al. (+-)-N6-endonorbornan-2-yl-9-methyladenine (N-0861) and its enantiomers: selective antagonists of A1-adenosine receptors in guinea pig isolated atria. , 1993, Journal of Pharmacology and Experimental Therapeutics.
[21] R F Bruns,et al. Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. , 1980, Canadian journal of physiology and pharmacology.
[22] J. Daly,et al. Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. , 1986, Journal of medicinal chemistry.
[23] G. Ghai,et al. Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines. , 1991, Journal of medicinal chemistry.
[24] R. Quinn,et al. A computer generated model of adenosine receptors rationalising binding and selectivity of receptor ligands , 1991 .
[25] A. Fasbender,et al. C-2 functionalized N6-cyclosubstituted adenosines : highly selective agonists for the adenosine A1 receptor , 1993 .
[26] A. Paterson,et al. Potencies of mioflazine and its derivatives as inhibitors of adenosine transport in isolated erythrocytes from different species , 1990, The Journal of pharmacy and pharmacology.
[27] J. Deckert,et al. Adenosine uptake site heterogeneity in the mammalian CNS? Uptake inhibitors as probes and potential neuropharmaceuticals. , 1988, Life sciences.
[28] R. G. Browne,et al. 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. , 1990, Journal of medicinal chemistry.
[29] U. Schwabe,et al. Characterization of Membrane‐Bound and Solubilized High‐Affinity Binding Sites for 5′‐N‐Ethylcarboxamido[3H]adenosine from Bovine Cerebral Cortex , 1993, Journal of neurochemistry.
[30] R. Olsson,et al. Use of Structure-Activity Relationships in the Study of Adenosine Receptors , 1985 .
[31] G. Sutherland,et al. Binding of the Adenosine A2 Receptor Ligand [3H]CGS 21680 to Human and Rat Brain: Evidence for Multiple Affinity Sites , 1990, Journal of neurochemistry.
[32] K. Jacobson,et al. A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. , 1987, Molecular pharmacology.
[33] G. Stiles. A1 Adenosine Receptor‐G Protein Coupling in Bovine Brain Membranes: Effects of Guanine Nucleotides, Salt, and Solubilization , 1988, Journal of neurochemistry.
[34] K. Jacobson,et al. [3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[35] H. van Belle,et al. Nucleoside transport inhibition for cardioprotection: New perspectives for the clinic , 1993 .
[36] M. Williams,et al. Adenosine A1 receptors in mammalian brain: Species differences in their interactions with agonists and antagonists , 1986 .
[37] J. Daly,et al. Caffeine and theophylline analogues: correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. , 1988, Life sciences.
[38] S Schiffmann,et al. RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. , 1990, Biochemical and biophysical research communications.
[39] K. Klotz,et al. 2',3'-Dideoxy-N6-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors. , 1988, European journal of pharmacology.
[40] K. Jacobson,et al. [3H]XAC (xanthine amine congener) is a radioligand for A2-adenosine receptors in rabbit striatum , 1991, Neurochemistry International.
[41] J. Fergus,et al. PD 115,199: An antagonist ligand for adenosine A2 receptors , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.
[42] W. Schiemann,et al. On the ability of endogenous adenosine to regulate purine nucleoside receptor binding of antagonists in smooth muscle membranes. , 1990, Journal of Pharmacology and Experimental Therapeutics.
[43] G. Ghai,et al. CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. , 1989, Journal of Pharmacology and Experimental Therapeutics.
[44] S. Snyder,et al. Adenosine receptors in brain membranes: binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[45] U. Schwabe,et al. Characterization of adenosine receptors in rat brain by (−)[3H]N6-phenylisopropyladenosine , 1980, Naunyn-Schmiedeberg's Archives of Pharmacology.
[46] B. Weeks,et al. Species differences in high‐affinity adenosine A2 binding sites in striatal membranes from mammalian brain , 1988 .
[47] J. Daly,et al. Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. , 1989, Journal of medicinal chemistry.
[48] R. Quinn,et al. An explanation of the substituent effect of 1,3,8-trisubstituted xanthines on adenosine A1/A2 affinity. , 1992 .
[49] K. Jacobson,et al. Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors. , 1989, Journal of medicinal chemistry.
[50] R. F. Bruns,et al. Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. , 1981, Biochemical pharmacology.
[51] K. Jacobson,et al. 8-Substituted xanthines as antagonists at A1- and A2-adenosine receptors. , 1988, Biochemical pharmacology.
[52] J. Fozard,et al. Adenosine A3 receptors 1 mediate hypotension in the angiotensin II‐supported circulation of the pithed rat , 1993, British journal of pharmacology.
[53] C. Müller,et al. Stimulation of calcium release by caffeine analogs in pheochromocytoma cells. , 1993, Biochemical pharmacology.
[54] M. Ueeda,et al. 2-(N'-alkylidenehydrazino)adenosines: potent and selective coronary vasodilators. , 1992, Journal of medicinal chemistry.
[55] G Vassart,et al. Selective amplification and cloning of four new members of the G protein-coupled receptor family. , 1989, Science.
[56] A. Matsuda,et al. Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity. , 1992, Journal of medicinal chemistry.
[57] D. Ukena,et al. [125I] N6-p-hydroxyphenylisopropyladenosine, a new ligand for Ri adenosine receptors , 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.
[58] A. Wauquier,et al. The nucleoside-transport inhibitor soluflazine (R 64 719) increases the effects of adenosine in the guinea-pig hippocampal slice and is antagonized by adenosine deaminase. , 1987, European journal of pharmacology.
[59] R. Midgett,et al. Adenosine deaminase inhibitors. Synthesis and biological evaluation of C1' and nor-C1' derivatives of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenine. , 1992, Journal of medicinal chemistry.
[60] H. W. Hamilton,et al. Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application. , 1985, Journal of medicinal chemistry.
[61] A. Matsuda,et al. Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects. , 1992, Journal of medicinal chemistry.
[62] A. IJzerman,et al. Inhibition of nucleoside transport by a new series of compounds related to lidoflazine and mioflazine. , 1989, European journal of pharmacology.
[63] J. Fergus,et al. Solubilities of Adenosine Antagonists Determined by Radioreceptor Assay , 1989, The Journal of pharmacy and pharmacology.
[64] S. Rivkees,et al. Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. , 1992, Molecular endocrinology.
[65] F. Gusovsky,et al. Frog secretions and hunting magic in the upper Amazon: identification of a peptide that interacts with an adenosine receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[66] G D Schuler,et al. A workbench for multiple alignment construction and analysis , 1991, Proteins.
[67] G. Cristalli,et al. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. , 1991, Journal of medicinal chemistry.
[68] A. IJzerman,et al. A steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptor. , 1992, Journal of medicinal chemistry.
[69] B. K. Trivedi,et al. [1,2,4]Triazolo[4,3-a]quinoxalin-4-amines: a new class of A1 receptor selective adenosine antagonists. , 1988, Journal of medicinal chemistry.
[70] J. Ribeiro,et al. Adenosine receptors and calcium: Basis for proposing a third (A3) adenosine receptor , 1986, Progress in Neurobiology.
[71] R. Thompson,et al. 2-(N'-aralkylidenehydrazino)adenosines: potent and selective coronary vasodilators. , 1992, Journal of medicinal chemistry.
[72] B. K. Trivedi,et al. C2,N6-disubstituted adenosines: synthesis and structure-activity relationships. , 1989, Journal of medicinal chemistry.
[73] R. A. Johnson,et al. Potent adenosine receptor antagonists that are selective for the A1 receptor subtype. , 1987, Molecular pharmacology.
[74] S. Rivkees,et al. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. , 1991, Molecular endocrinology.
[75] A. Paoletti,et al. Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective desensitization of adenosine A1 but not A2 receptors. , 1992, European journal of pharmacology.
[76] K. Jacobson,et al. Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[77] J. Uzawa,et al. Restriction of the C6N6 bond rotation of adenosine compounds investigated by 1H‐ and 15N‐NMR spectra , 1988 .
[78] M. Parmentier,et al. The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. , 1991, The EMBO journal.
[79] J. Linden,et al. 125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors. , 1988, Journal of medicinal chemistry.
[80] T. Heffner,et al. Ribose-modified adenosine analogues as adenosine receptor agonists. , 1986, Journal of medicinal chemistry.
[81] N P Peet,et al. A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors. , 1990, Journal of medicinal chemistry.
[82] K. Jacobson,et al. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. , 1993, Journal of medicinal chemistry.
[83] J. Shimada,et al. 8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors. , 1992, Journal of medicinal chemistry.
[84] R. Henderson,et al. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. , 1990, Journal of molecular biology.
[85] W. Padgett,et al. Interaction of Anticonvulsant Drugs with Adenosine Receptors in the Central Nervous System , 1984, Epilepsia.
[86] S. Schiffmann,et al. Adenosine A2a receptor expression in striatal neurons: Implications for basal ganglia pathophysiology , 1993 .
[87] A. Matsuda,et al. Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects. , 1992, Journal of medicinal chemistry.
[88] R. North,et al. Functional expression of adenosine A2b receptor in Xenopus oocytes. , 1993, Molecular pharmacology.
[89] J. Daly,et al. Imidazodiazepinediones: a new class of adenosine receptor antagonists. , 1990, Journal of Medicinal Chemistry.
[90] G. Lu,et al. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. , 1986, Molecular pharmacology.
[91] A. Ménez,et al. Molecular cloning of a cDNA encoding the precursor of adenoregulin from frog skin. Relationships with the vertebrate defensive peptides, dermaseptins. , 1993, Biochemical and biophysical research communications.
[92] J. Daly,et al. 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs. , 1988, Life sciences.
[93] G. Stiles. Adenosine receptors: structure, function and regulation , 1986 .
[94] K. Klotz,et al. 2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors. , 1992, Journal of medicinal chemistry.
[95] G. Ghai,et al. 2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands. , 1990, Journal of medicinal chemistry.
[96] K. Jacobson,et al. Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors. , 1987, Journal of medicinal chemistry.
[97] K. Jacobson,et al. Molecular probes for extracellular adenosine receptors. , 1987, Biochemical pharmacology.
[98] K. Kubo,et al. Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure. , 1992, Journal of medicinal chemistry.
[99] A. Galione. Ca(2+)-induced Ca2+ release and its modulation by cyclic ADP-ribose. , 1992, Trends in pharmacological sciences.
[100] J. Daly,et al. Structure-activity relationships for N6-substituted adenosines at a brain A1-adenosine receptor with a comparison to an A2-adenosine receptor regulating coronary blood flow. , 1986, Biochemical pharmacology.
[101] T. Hasegawa,et al. Effects of alkyl substitutions of xanthine skeleton on bronchodilation. , 1992, Journal of medicinal chemistry.
[102] T. Heffner,et al. N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. , 1987, Journal of medicinal chemistry.
[103] K. Jacobson,et al. Novel therapeutics acting via purine receptors. , 1991, Biochemical pharmacology.
[104] J. Fergus,et al. Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.
[105] M. Ueeda,et al. 2-Phenylethoxy-9-methyladenine: an adenosine receptor antagonist that discriminates between A2 adenosine receptors in the aorta and the coronary vessels from the guinea pig. , 1993, The Journal of pharmacology and experimental therapeutics.
[106] K. Jacobson,et al. A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. , 1992, Molecular pharmacology.
[107] J. Linden,et al. 125I-BW-A844U, an antagonist radioligand with high affinity and selectivity for adenosine A1 receptors, and 125I-azido-BW-A844U, a photoaffinity label. , 1988, Molecular pharmacology.
[108] A Sattin,et al. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices. , 1970, Molecular pharmacology.
[109] W. Meyerhof,et al. Molecular cloning of a novel putative G‐protein coupled receptor expressed during rat spermiogenesis , 1991, FEBS letters.
[110] S. Klumpp,et al. Pyrrolo[2,3-d]pyrimidines as inhibitors of cAMP-phosphodiesterase. Structure-activity relationship. , 1989, Biochemical pharmacology.
[111] G. Ghai,et al. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. , 1988, Journal of medicinal chemistry.
[112] K. Jacobson,et al. Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists. , 1992, Journal of medicinal chemistry.
[113] N. Wiklund,et al. Subclassification of Neuronal Adenosine Receptors , 1990 .
[114] C. Müller,et al. Methylxanthines block antigen-induced responses in RBL-2H3 cells independently of adenosine receptors or cyclic AMP: evidence for inhibition of antigen binding to IgE. , 1991, The Journal of pharmacology and experimental therapeutics.
[115] C. Müller,et al. Caffeine analogs: structure-activity relationships at adenosine receptors. , 1991, Pharmacology.
[116] S. Hurt,et al. [3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain. , 1992, The Journal of pharmacology and experimental therapeutics.
[117] H. Baer,et al. 5'-Deoxy-5'-methylthioadenosine: a nucleoside which differentiates between adenosine receptor types. , 1988, Biochemical pharmacology.
[118] R. Quinn,et al. The three binding domain model of adenosine receptors: molecular modeling aspects. , 1992, Journal of medicinal chemistry.
[119] K. Jacobson,et al. Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. , 1993, Journal of medicinal chemistry.
[120] J. Baldwin. The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.
[121] C. J. Blankley,et al. N6-substituted adenosine receptor agonists: potential antihypertensive agents. , 1991, Journal of medicinal chemistry.
[122] A. Tucker,et al. Cloning and expression of a bovine adenosine A1 receptor cDNA , 1992, FEBS letters.
[123] R. Wolfenden,et al. Transition-state discrimination by adenosine deaminase from Aspergillus oryzae. , 1993, Biochimica et biophysica acta.
[124] K. Jacobson,et al. The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. , 1991, Molecular pharmacology.
[125] S. Krawczyk,et al. Rapid communication: Inhibition of adenosine deaminase by azapurine ribonucleosides , 1992 .
[126] S. Snyder,et al. Adenosine as a neuromodulator. , 1985, Annual review of neuroscience.
[127] F. Kuhn,et al. Selective A1-Antagonists for Treatment of Cognitive Deficits , 1991 .
[128] J. Pearson,et al. The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. , 1983, The Biochemical journal.
[129] R. Agarwal. Inhibitors of adenosine deaminase. , 1982, Pharmacology & therapeutics.
[130] R. Vestal,et al. Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor. , 1993, The American journal of physiology.
[131] T J Furlong,et al. Molecular characterization of a human brain adenosine A2 receptor. , 1992, Brain research. Molecular brain research.
[132] K. Jacobson,et al. Adenosine A1 receptor and ligand molecular modeling , 1993 .
[133] J. Daly,et al. N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. , 1991, Journal of medicinal chemistry.
[134] L. Arroyo,et al. 2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor. , 1991, Journal of medicinal chemistry.
[135] A. Szent-Györgyi,et al. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart 1 , 1929, The Journal of physiology.
[136] Zhenqiang Yang,et al. Regiospecific introduction of carbon-3 formyl group to 2,5-dialkyl-7-methoxy-benzo[b] furans : Synthesis of potential ligands for adenosine A1 receptors , 1992 .
[137] K. Klotz,et al. Barbiturates Are Selective Antagonists at A1 Adenosine Receptors , 1985, Journal of neurochemistry.
[138] A. IJzerman,et al. Mapping the N6-region of the adenosine A1 receptor with computer graphics. , 1989, European journal of pharmacology.
[139] J. N. Wells,et al. Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors. , 1990, Journal of medicinal chemistry.
[140] W. Moos,et al. N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists. , 1985, Journal of medicinal chemistry.
[141] K. Jacobson,et al. A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dipropylxanthine. , 1986, Molecular pharmacology.
[142] G. Lu,et al. Adenosine Receptor Subtypes: Binding Studies , 1987 .
[143] J. Daly,et al. Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors. , 1991, Journal of medicinal chemistry.
[144] K. Mullane,et al. Acadesine: Prototype adenosine regulating agent for treating myocardial ischemia‐reperfusion injury , 1993 .
[145] J. Daly,et al. Agonist activity of 2- and 5'-substituted adenosine analogs and their N6-cycloalkyl derivatives at A1- and A2-adenosine receptors coupled to adenylate cyclase. , 1992, Biochemical pharmacology.
[146] K. Klotz,et al. Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. , 1988, Journal of medicinal chemistry.
[147] E. M. Adler,et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. , 1992, Brain research. Molecular brain research.
[148] J. Daly. Adenosine receptors: targets for future drugs. , 1982, Journal of medicinal chemistry.
[149] Zhenqiang Yang,et al. Compounds from Danshen. Part 7. Regioselective introduction of carbon-3 substituents to 5-alkyl-7-methoxy-2-phenylbenzo[b]furans: synthesis of a novel adenosine A1 receptor ligand and its derivatives , 1992 .
[150] K. Jacobson,et al. Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. , 1985, Journal of medicinal chemistry.
[151] G. Cristalli,et al. Adenosine and 2-Chloroadenosine Deaza-Analogues as Adenosine Receptor Agonists1 , 1985 .
[152] M. Williams,et al. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.
[153] G. Stiles,et al. Reciprocal modulation of agonist and antagonist binding to A1 adenosine receptors by guanine nucleotides is mediated via a pertussis toxin-sensitive G protein. , 1988, The Journal of pharmacology and experimental therapeutics.
[154] B. Hamprecht,et al. Nomenclature of adenosine receptors , 1985 .
[155] J. Miller,et al. In vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): a selective, orally active A1 adenosine receptor antagonist. , 1993, The Journal of pharmacology and experimental therapeutics.
[156] K. Kubo,et al. 8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities. , 1991, Journal of medicinal chemistry.
[157] Adriaan P. IJzerman,et al. Xanthine-7-Ribosides as Adenosine Al Receptor Antagonists: Further Evidence for Adenosine's Anti Mode of Binding , 1990 .
[158] S E Ealick,et al. Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[159] Zhenqiang Yang,et al. Naturally occurring benzofuran: isolation, structure elucidation and total synthesis of 5-(3-hydroxypropyl)-7-methoxy-2-(3′-methoxy-4′-hydroxyphenyl)-3-benzo[b]furancarbaldehyde, a novel adenosine A1 receptor ligand isolated from salvia miltiorrhiza bunge (danshen) , 1991 .
[160] K. Jacobson,et al. Adenosine analogs with covalently attached lipids have enhanced potency at A1‐adenosine receptors , 1987, FEBS letters.
[161] F Suzuki,et al. (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. , 1992, Journal of medicinal chemistry.
[162] H. V. van Vlijmen,et al. A model for the antagonist binding site on the adenosine A1 receptor, based on steric, electrostatic, and hydrophobic properties. , 1990, Journal of medicinal chemistry.
[163] G. Stiles,et al. Characterization of the A1 Adenosine Receptor‐Adenylate Cyclase System of Cerebral Cortex Using an Agonist Photoaffinity Ligand , 1986, Journal of neurochemistry.
[164] J. Daly,et al. 1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. , 1985, Journal of medicinal chemistry.
[165] M. Williams,et al. Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.
[166] K. Jacobson,et al. Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors. , 1988, Biochemical pharmacology.
[167] J. Shine,et al. Molecular cloning and expression of an adenosine A2b receptor from human brain. , 1992, Biochemical and biophysical research communications.
[168] J. Daly,et al. Definition of subclasses of adenosine receptors associated with adenylate cyclase: interaction of adenosine analogs with inhibitory A1 receptors and stimulatory A2 receptors. , 1987, Canadian journal of physiology and pharmacology.
[169] H. Simmonds,et al. Purines: Basic and Clinical Aspects , 1991, Springer Netherlands.
[170] T. Hasegawa,et al. Bronchodilator activity of xanthine derivatives substituted with functional groups at the 1- or 7-position. , 1993, Journal of Medicinal Chemistry.
[171] J Hoflack,et al. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. , 1991, Molecular pharmacology.
[172] J. Daly,et al. 8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors. , 1988, Journal of medicinal chemistry.
[173] C. Gerfen,et al. Cloning and expression of an A1 adenosine receptor from rat brain. , 1991, Molecular pharmacology.
[174] Adriaan P. IJzerman,et al. Mapping the xanthine C8-region of the adenosine A1 receptor with computer graphics☆ , 1991 .
[175] Y. Chern,et al. Molecular cloning of a novel adenosine receptor gene from rat brain. , 1992, Biochemical and biophysical research communications.
[176] J. Daly,et al. Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. , 1993, Pharmacology.
[177] B. F. Becker,et al. Topics and Perspectives in Adenosine Research , 1987, Springer Berlin Heidelberg.
[178] I. Fox,et al. Soluble and membrane-associated human low-affinity adenosine binding protein (adenotin): properties and homology with mammalian and avian stress proteins. , 1990, Biochemistry.
[179] R. A. Johnson,et al. Irreversible inactivation of adenylyl cyclase by the "P"-site agonist 2',5'-dideoxy-,3'-p-fluorosulfonylbenzoyl adenosine. , 1990, The Journal of biological chemistry.
[180] J Hoflack,et al. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.
[181] K. Jacobson,et al. Species differences in structure‐activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors , 1986, FEBS letters.
[182] A. Bridges,et al. N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor. , 1988, Journal of medicinal chemistry.
[183] J. Linden,et al. Indirect effect of guanine nucleotides on antagonist binding to A1 adenosine receptors: occupation of cryptic binding sites by endogenous vesicular adenosine. , 1992, Molecular pharmacology.